Status:
RECRUITING
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
Lead Sponsor:
Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
Eligibility Criteria
Inclusion Criteria:
- Able and willing to provide a written informed consent.
- Age ≥ 18 years old and < 80 years old.
- Male or female.
Exclusion Criteria:
- Acute pancreatitis within 3 months or within 4 weeks or planned for plasma exchange treatment.
- Malignant tumors within 5 years.
- Severe cardiovascular or cerebrovascular diseases.
- Severe trauma or surgery within 6 months or severe infection within 3 months.
- Previous diagnosed diseases affecting lipid levels.
- Patients with unstable or severe diseases assessed as at risk by the investigator.
- Uncontrolled hypertension.
- Weight loss within 2 months or planned surgery causing unstable weight.
- Uncontrolled diabetes.
- Combined hyperthyroidism or hypothyroidism.
- History of drug or alcohol abuse.
- Significantly abnormal liver or kidney function.
- Significantly abnormal blood routine.
- Significantly abnormal thyroid function.
- Participated in clinical research within 3 months.
- Pregnant or lactating women, or refusing contraception.
Key Trial Info
Start Date :
August 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07100418
Start Date
August 12 2025
End Date
January 1 2027
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030